Risk Factors Update Summary

• Legislation like the Inflation Reduction Act may impact ENTADFI's marketability and profitability. This could reduce profitability significantly due to price negotiations and rebates.
• The company reported a net loss of $37.4 million for 2023, up from $13.4 million in 2022. This significant increase raises concerns about financial stability.
• We face an inherent risk of product liability exposure related to the commercialization of our products. This change might result in substantial liabilities if claims arise.
• As of December 31, 2023, the accumulated deficit increased to $56.8 million from $19.4 million, indicating worsening financial health.
• The U.S. Supreme Court's recent rulings may weaken patent rights, particularly affecting diagnostic patents. This uncertainty could significantly impact our ability to secure future patents.
• The company generated 100% of its revenue from one customer, Immunovia AB, in 2023. This concentration poses significant risks if demand declines.
• We may have violated Section 13(k) of the Exchange Act, potentially leading to civil sanctions. Unauthorized charges ranged from approximately $257,000 to $405,000 for 2022.
• If we fail to increase sales and marketing capabilities, revenue growth may be negatively affected. Significant resources will be dedicated to expanding distribution networks.
• The company has incurred substantial operating losses since inception and expects to continue incurring significant losses for the foreseeable future.
• We may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic tests and services. This could significantly impact revenue.
• Nasdaq notified us of non-compliance with the Bid Price Rule due to a closing bid price below $1.00. We have until March 16, 2024, to regain compliance.
• The company may face challenges in resuming ENTADFI commercialization due to competition from established generic drugs. This could limit market penetration and revenue growth.
• Conditions in the global economy may adversely affect our business, financial condition, and results of operations. This change highlights potential vulnerabilities in economic downturns.
• The company may be obligated to cash settle the Series B Preferred Stock, potentially costing approximately $44.8 million based on stock price.
• The company is currently in discussions with Veru regarding $10 million in payments due, which could impact operations if unresolved.
• We may be unable to attract and retain qualified scientists and technicians due to competition. This could limit our ability to support research and development programs.
• Manufacturing delays could occur if third-party manufacturers prioritize other products over ENTADFI or Proclarix. This may impair supply and commercialization efforts.
• The development of new liquid biopsy and imaging technologies could negatively impact demand for our products. This change emphasizes the need for continuous innovation to remain competitive.